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Abstract
Background: Neurofibromatosis type 1 (NF1) is a rare multisystem genetic disorder. During the course of the
disease it can be rarely complicated with pulmonary hypertension (PH) which confers a dismal prognosis.
Case presentation: We describe the case of a 57-year-old female patient with NF1 complicated by severe
precapillary PH despite dual disease-specific oral combination therapy. The patient was treated with initial atrial
septostomy followed by administration of high-dose subcutaneous treprostinil with a favorable medium-term
clinical and hemodynamic response.
Conclusions: PH secondary to NF1 may be successfully treated with the combination of atrial septostomy and PH
targeted therapy in selected patients.
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Background
Neurofibromatosis type 1 (NF1) is a genetic disease
with a prevalence of 1:3500 in the general population,
transmitted with the autosomal dominant inheritance
pattern and with full penetrance characterized by
prominent skin features (hyperpigmented macules,
termed café-au-lait spots and nerve tumors), optical
tumors and other central nervous system tumors,
certain bony abnormalities, some learning deficits and
an increased risk of certain non-nervous system can-
cers [1]. Mutations of the NF1 gene, which encodes
neurofibromin and is located at chromosome 17q11.2,
a negative regulator of the ras signal transduction
pathway that has a role in both tumor suppression
and regulation of cell growth and proliferation, are
responsible for the NF1 [2].
A rare still morbid complication of NF1 is pulmonary
hypertension (PH) which confers a dismal prognosis
overall. To the best of our knowledge this is the first
documented report of successful treatment of PH second-
ary to NF1 with atrial septostomy followed by escalation
of PH targeted treatment.
Case presentation
A 57-year-old female patient with a history of NF1 and
PH initially diagnosed 3 years ago, already on conventional
treatment with supplemental oxygen and anticoagulation,
as well as disease-specific double oral combination ther-
apy (ambrisentan 10 mg od and tadalafil 40 mg od) was
admitted to the hospital because of worsening dyspnea on
mild exertion and a presyncopal episode.
Her past medical history was notable for surgically
repaired pyloric stenosis and 2 abortions during the
third trimester of gestation due to intrauterine fetal
death, followed by a successful pregnancy. The patient
had already undergone an extensive workup which
excluded known causes of PH. Lung ventilation/perfu-
sion scan was not suggestive for chronic thrombo-
embolic disease and high-resolution CT of the lungs was
negative for interstitial lung disease. Blood tests excluded
other causes of pulmonary hypertension.
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Considering the patient’s clinical deterioration, the
decision was made to proceed immediately with atrial
septostomy, due to inherent difficulties in the reimburse-
ment of prostanoids in our hospital at that time. The
patient had an uneventful procedure with graded balloon
dilation of the interatrial septum with gradually increas-
ing inflated balloons diameter of 6, 8 and 10 mm. A
moderate decrease in right atrial pressure (Fig. 1), a mild
increase in cardiac index and, as expected, a decrease in
SaO2 was noted (Table 1) due to the right-to-left shunting
through the atrial septum. The patient remained clinically
and hemodynamically stable and was discharged a few
days later.
After an initial modest improvement in symptoms,
six-minute walk test (6MWT) and NT-proBNP at
2 months, access to prostanoids was eventually gained
and the patient was started on subcutaneous treprostinil
with gradual increase in the administered dose up to
100 ng/kg/min in a time period of 7 months.
The patient during a follow-up period of 2 years
demonstrated gradual improvement and at present
remains in World Health Organization class 2 with
significant hemodynamic improvement (Table 1). A
recent transthoracic echocardiogram demonstrated the
positive remodeling of the right ventricle (Fig. 2a, b)
and the persistence of the atrial septostomy (Fig. 2c).
The shunt flow was small and at rest was from the
left atrium to the right atrium but after 2 min of iso-
metric exercise (hand grip and feet in cycling pos-
ition) the shunt became right-to-left (Fig. 2d).
Discussion
A few cases suggesting an association of NF1 gene muta-
tion and precapillary PH have been published [3, 4]. Plexi-
form lesions similar to those observed in human idiopathic
PAH have been described, implying that vasculopathy of
neurofibromatosis might underlie the pathophysiology of
PH, a severe complication, which seems to show a predi-
lection for women with severe clinical and hemodynamic
impairment and a poor outcome [5].
Herein, we report a case of a patient with NF1 and severe
precapillary PH, without parenchymal lung disease, yet with
prominent pulmonary vascular involvement, treated with
atrial septostomy, followed by the administration of sub-
cutaneous treprostinil. The medium-term clinical response
after 2 years was impressive with improvement in her func-
tional class, 6MWT distance, hemodynamic parameters
and NT-proBNP. To the best of our knowledge this is the
first published case of PH secondary to neurofibromatosis
treated successfully with the combination of atrial septost-
omy and aggressive PH targeted therapy.
The favorable clinical response of our patient to the
atrial septostomy and the further gradual, but more pro-
nounced, improvement with the chronic administration of
subcutaneous treprostinil suggests that pulmonary vascu-
lopathy is the underlying mechanism of PH in these
patients. The creation of a shunt that decreases the pre-
load of the right ventricle and increases that of the left
ventricle with concomitant increase in the cardiac output
makes it easier to initiate and uptitrate the prostanoid
infusion. The long-term effect of the persistence of the
Fig. 1 a Simultaneous recording of right atrial (RA) and left atrial (LA) pressures, before the creation of the balloon atrial septostomy. b
Simultaneous recording of right atrial (RA) and left ventricular (LV) pressures, demonstrating the fall in the mean RA and the increase in the LV
diastolic pressures as compared to the LA pressure in A. The aortic pressure (AO) is recorded on a pressure scale of 0–200 mmHg. Mean pressures
are in parentheses
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Table 1 Serial hemodynamic, functional and neurohormonal measurements






HR (beats/min) 76 91 90 71 70
RAP (mmHg) (3) (11) (7) (4) (6)
PAP (mmHg) 68/26 (43) 130/57 (84) 135/56 (84) 106/36 (63) 77/30 (49)
PAWP/LAP*
(mmHg)
(6) (2)* (7)* (7) (9)*
Ao (mmHg) 130/68 (93) 122/65 (84) 124/65 (84) 119/71 (87) 128/65 (85)
PVR (WU) 8.3 27.1 26.3 11.6 6.8
CI (l/min/m2) 2.9 1.9 2.0 3.1 3.7
SaO2 (%) 97 at rest
90 (during exercise)




6MWT (m) 489 230a 335b 345 399
NT-proBNP (pg/ml) 125 3402a 1507b NA 161
Mean pressures are shown in parentheses
BAS: balloon atrial septostomy, HR: heart rate, RAP: Right atrial pressure, PAP: Pulmonary artery pressure, LAP: Left atrial pressure, PCWP: Pulmonary capillary wedge
pressure, Ao: Aortic pressure, PVR: Pulmonary vascular resistance, CI: Cardiac index, WU: Wood Units, 6MWT: 6-min walking test, NT-proBNP: N-terminal pro-brain
natriuretic peptide, NA: not available
*Asterisk indicates that the pressure was measured in the left atrium
a2 weeks prior to the procedure
b1 month after the procedure
Fig. 2 a, b Short-axis transthoracic echocardiographic view demonstrating the positive remodelling of the right ventricle (RV) 2 years after the
atrial septostomy and the initiation of subcutaneous treprostinil. LV = left ventricle c Subxiphoid echocardiographic view of the persistent flow
from the left atrium (LA) to the right atrium (RA) at rest d Reversal of flow from RA to LA after isometric exercise
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shunt in our case, following the decrease in the right sided
pressures on chronic treprostinil therapy, is not known;
whether the reversal of the shunt during exercise by
decreasing the load on the right ventricle will continue to
be beneficial, despite the arterial oxygen desaturation, is
not clear [6].
There are very few cases in the literature with the
utilization of PAH-targeted therapies in these patients
[7–9]. Our patient improved significantly after the initi-
ation of treprostinil, while double oral therapy had ini-
tially failed. The development of PH in patients with
NF1 confers a dismal prognosis and therefore, the earlier
and aggressive treatment with prostanoids should be
considered. Finally, listing these patients for lung trans-
plantation is a matter of debate, since a higher than the
general population incidence of malignancies has been
described [10].
Conclusions
This report demonstrates the successful management of
a patient with PH secondary to NF1 with atrial septost-
omy in conjunction with PAH targeted therapy. Looking
ahead, national and international prospective registries
will shed light on the pathophysiology, and especially
optimal therapy and prognosis of neurofibromatosis-
associated PH especially in the modern era of targeted
PAH treatment.
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